Signed in as:
filler@godaddy.com
MK-801-induced Schizophrenia Model
Schizophrenia is a severe mental disorder affecting approximately 1% of the global population, often characterized by emotional impairment, cognitive deficits, and social dysfunction. To model these complex symptoms, Naason Science uses the MK-801-induced schizophrenia model, which involves administering multiple doses of the non-competitive NMDA receptor antagonist MK-801. This compound induces behaviors in rodents that closely mirror the cognitive and social impairments observed in schizophrenia, such as disruptions in associative memory and deficits in attention and social interactions.
Our MK-801 model provides a valuable platform for studying schizophrenia's underlying mechanisms and assessing the efficacy of potential therapeutic compounds targeting cognitive and social deficits. This model is essential for advancing the development of treatments aimed at improving quality of life for individuals with schizophrenia.
Naason Science models of PTSD in rat and minipig
PTSD is a serious anxiety disorder that can lead to intense fear and anxiety. Current medication is unspecific and ineffective, with a number of side effects. One limiting factor in the development of treatment for PTSD is the lack of valid, translational models. Naason Science has been developing models of PTSD in the rat and has initiated a development program in a larger animal - the minipig, based on a multi-faceted prolonged stress paradigm, so as to test the efficacy of new compounds.
For more information please contact info@naasonscience.com
Naason Science to be part of Consortium
Naason Science is part of a consortium for the development of a new potential treatment to reduce fear memory in post-traumatic stress disorder (PTSD). By selectively targeting mGlu7 with NAMs, the brain circuitries involved in fear and anxiety can be precisely modulated, potentially resulting in higher efficacy and fewer side effects.
Please find more information about the project here.
